JP2014532620A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532620A5 JP2014532620A5 JP2014536398A JP2014536398A JP2014532620A5 JP 2014532620 A5 JP2014532620 A5 JP 2014532620A5 JP 2014536398 A JP2014536398 A JP 2014536398A JP 2014536398 A JP2014536398 A JP 2014536398A JP 2014532620 A5 JP2014532620 A5 JP 2014532620A5
- Authority
- JP
- Japan
- Prior art keywords
- influenza
- virus
- immunogenic composition
- motomeko
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 claims description 55
- 230000002163 immunogen Effects 0.000 claims description 52
- 241000713196 Influenza B virus Species 0.000 claims description 34
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 239000002671 adjuvant Substances 0.000 claims description 14
- 239000007764 o/w emulsion Substances 0.000 claims description 9
- 230000003053 immunization Effects 0.000 claims description 8
- 241000712431 Influenza A virus Species 0.000 claims description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- 206010069767 H1N1 influenza Diseases 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 229960003971 influenza vaccine Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 201000010740 swine influenza Diseases 0.000 claims description 2
- 230000005847 immunogenicity Effects 0.000 claims 2
- 208000037798 influenza B Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 229960005486 vaccine Drugs 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161627995P | 2011-10-20 | 2011-10-20 | |
| US61/627,995 | 2011-10-20 | ||
| PCT/IB2012/055751 WO2013057715A1 (en) | 2011-10-20 | 2012-10-19 | Adjuvanted influenza b virus vaccines for pediatric priming |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014532620A JP2014532620A (ja) | 2014-12-08 |
| JP2014532620A5 true JP2014532620A5 (enExample) | 2015-12-03 |
Family
ID=47297335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014536398A Ceased JP2014532620A (ja) | 2011-10-20 | 2012-10-19 | 小児の初回免疫のためのアジュバント添加インフルエンザｂウイルスワクチン |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20140248320A1 (enExample) |
| EP (1) | EP2768528A1 (enExample) |
| JP (1) | JP2014532620A (enExample) |
| AU (1) | AU2012324398A1 (enExample) |
| CA (1) | CA2852857A1 (enExample) |
| WO (1) | WO2013057715A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2655714T3 (es) | 2009-02-26 | 2018-02-21 | The University Of North Carolina At Chapel Hill | Sistema intervencionista de administración de fármacos |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| KR101370512B1 (ko) | 2013-06-07 | 2014-03-06 | 재단법인 목암생명공학연구소 | 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법 |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| US10872313B2 (en) | 2015-06-02 | 2020-12-22 | ROCA Medical Ltd. | Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy |
| DK4023249T3 (da) | 2014-04-23 | 2025-01-13 | Modernatx Inc | Nukleinsyrevacciner |
| US10548974B2 (en) * | 2015-06-02 | 2020-02-04 | ROCA Medical Ltd. | Therapeutic treatment kit for allergies based on DNA profiles |
| DK3350157T3 (da) | 2015-09-17 | 2022-02-14 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler |
| MD3386484T2 (ro) | 2015-12-10 | 2022-11-30 | Modernatx Inc | Compoziții și metode de livrare a unor agenți terapeutici |
| AU2016377681B2 (en) | 2015-12-22 | 2021-05-13 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| ES2911186T3 (es) | 2017-03-15 | 2022-05-18 | Modernatx Inc | Formas cristalinas de aminolípidos |
| AU2018234692B2 (en) | 2017-03-15 | 2022-06-02 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| CA3080656A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| US12263248B2 (en) | 2018-09-19 | 2025-04-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| EP4509118A3 (en) | 2018-09-19 | 2025-05-14 | ModernaTX, Inc. | High-purity peg lipids and uses thereof |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| CA3154618A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4060082A (en) | 1976-08-16 | 1977-11-29 | Mpl, Inc. | Dual-ingredient medication dispenser |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| JPH0614756Y2 (ja) | 1991-06-26 | 1994-04-20 | 株式会社アルテ | 組み立て式の２室式容器兼用注射器 |
| US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| US5496284A (en) | 1994-09-27 | 1996-03-05 | Waldenburg; Ottfried | Dual-chamber syringe & method |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| WO1998001174A1 (fr) | 1996-07-05 | 1998-01-15 | Debiotech S.A. | Seringue a chambre double permettant le melange de deux produits avant leur injection |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| WO1998046262A1 (en) | 1997-04-16 | 1998-10-22 | Connaught Laboratories, Inc. | Anti-influenza compositions supplemented with neuraminidase |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| AU9785598A (en) | 1997-10-03 | 1999-04-27 | Texas Pharmaceuticals, Inc. | Improved dual chamber syringe apparatus |
| US5971953A (en) | 1998-01-09 | 1999-10-26 | Bachynsky; Nicholas | Dual chamber syringe apparatus |
| JP2002513773A (ja) | 1998-05-07 | 2002-05-14 | コリクサ コーポレイション | アジュバント組成物及びその使用法 |
| DE19835749C1 (de) | 1998-08-07 | 2000-02-03 | Dieter Perthes | Fertig-Spritze für nicht-stabile Arzneimittel |
| US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
| EP2345716B1 (en) | 1999-04-06 | 2015-01-14 | Wisconsin Alumni Research Foundation | Recombinant influenza viruses for vaccines and gene therapy |
| DE122007000070I1 (de) | 1999-07-14 | 2008-01-31 | Sinai School Medicine | In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren |
| DE60142506D1 (de) | 2000-03-03 | 2010-08-19 | Chemo Sero Therapeut Res Inst | In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle |
| DE60137345D1 (de) | 2000-04-28 | 2009-02-26 | St Jude Childrens Res Hospital | Dna-transfektionssystem zur erzeugung von infektiösen negativsträngigen rna virus |
| FR2808803B1 (fr) | 2000-05-11 | 2004-12-10 | Agronomique Inst Nat Rech | Cellules es modifiees et gene specifique de cellules es |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| CA2438942A1 (en) | 2001-02-23 | 2002-09-26 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
| US20040096463A1 (en) | 2001-02-23 | 2004-05-20 | Nathalie Garcon | Novel vaccine |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| FR2832423B1 (fr) | 2001-11-22 | 2004-10-08 | Vivalis | Systeme d'expression de proteines exogenes dans un systeme aviaire |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| US20080234632A1 (en) | 2004-03-23 | 2008-09-25 | Mitsuru Hasegawa | Pre-Filled Syringe |
| UA89631C2 (en) | 2004-04-05 | 2010-02-25 | Пфайзер Продактс Инк. | Vaccine composition |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| NZ551640A (en) | 2004-05-20 | 2010-05-28 | Id Biomedical Corp | Process for the production of an influenza vaccine |
| EP2578229B1 (en) | 2004-09-09 | 2013-07-10 | Novartis Vaccines and Diagnostics GmbH | Decreasing potential iatrogenic risks associated with vaccine antigens |
| CN101189326B (zh) | 2004-12-23 | 2013-06-12 | 米迪缪尼有限公司 | 用于病毒增殖的非致瘤性mdck细胞系 |
| AU2005318087B2 (en) | 2004-12-24 | 2011-04-21 | Abbott Biologicals B.V. | Rescue of influenza virus |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| HUE049580T2 (hu) | 2006-01-27 | 2020-09-28 | Seqirus Uk Ltd | Hemagglutinint és mátrixfehérjéket tartalmazó, influenza elleni oltóanyagok |
| CN101522218B (zh) | 2006-10-12 | 2012-09-26 | 葛兰素史密丝克莱恩生物有限公司 | 包含水包油乳液佐剂的疫苗 |
| PL2121011T3 (pl) * | 2006-12-06 | 2014-10-31 | Novartis Ag | Szczepionki zawierające antygeny czterech szczepów wirusa grypy |
| PE20090146A1 (es) * | 2007-04-20 | 2009-03-23 | Glaxosmithkline Biolog Sa | Composicion inmunogenica contra el virus influenza |
| WO2009071633A1 (en) * | 2007-12-06 | 2009-06-11 | Glaxosmithkline Biologicals S.A. | Influenza composition |
| US8506966B2 (en) * | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
| ES2537785T3 (es) * | 2009-05-08 | 2015-06-12 | Sciclone Pharmaceuticals, Inc. | Péptidos de alfa timosina como potenciadores de vacunas |
-
2012
- 2012-10-19 WO PCT/IB2012/055751 patent/WO2013057715A1/en not_active Ceased
- 2012-10-19 US US14/352,955 patent/US20140248320A1/en not_active Abandoned
- 2012-10-19 CA CA2852857A patent/CA2852857A1/en not_active Abandoned
- 2012-10-19 AU AU2012324398A patent/AU2012324398A1/en not_active Abandoned
- 2012-10-19 JP JP2014536398A patent/JP2014532620A/ja not_active Ceased
- 2012-10-19 EP EP12797981.3A patent/EP2768528A1/en not_active Withdrawn
-
2018
- 2018-11-16 US US16/193,024 patent/US20190247489A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014532620A5 (enExample) | ||
| Shah et al. | Overview of vaccine adjuvants: introduction, history, and current status | |
| Peek et al. | Nanotechnology in vaccine delivery | |
| JP2011504486A5 (enExample) | ||
| JP2016185988A5 (enExample) | ||
| TW200722101A (en) | Novel composition | |
| Wilschut | Influenza vaccines: the virosome concept | |
| JP2009539965A5 (enExample) | ||
| Banzhoff et al. | MF59®‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis | |
| Haddadin et al. | Alternative strategies of posttransplant influenza vaccination in adult solid organ transplant recipients | |
| RU2009144125A (ru) | Виросомы, содержащие гемагглютинин, полученный из вируса гриппа, вырабатываемого в клеточной линии; композиции, методы получения и применение на их основе | |
| JP2016506416A5 (enExample) | ||
| Atmar et al. | Adjuvants for pandemic influenza vaccines | |
| Parodi et al. | Inactivated influenza vaccines: recent progress and implications for the elderly | |
| NZ594482A (en) | Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant | |
| EA200900024A1 (ru) | Противогриппозная вакцина | |
| Jang et al. | Cross-protective immune responses elicited by live attenuated influenza vaccines | |
| Romeli et al. | Multi-epitope peptide-based and vaccinia-based universal influenza vaccine candidates subjected to clinical trials | |
| Clegg et al. | Clinical vaccine development for H5N1 influenza | |
| RU2017137357A (ru) | Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал | |
| JP2016508999A5 (enExample) | ||
| EA023662B1 (ru) | Вакцины против гриппа со сниженным количеством сквалена | |
| Rambe et al. | Safety and mechanism of action of licensed vaccine adjuvants | |
| JP2009514839A5 (enExample) | ||
| Ju et al. | Heat shock protein gp96 adjuvant induces T cell responses and cross-protection to a split influenza vaccine |